FCMT
VRTX icon

Founders Capital Management (Texas)’s Vertex Pharmaceuticals VRTX Stock Holding History

Founders Capital Management (Texas)’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-75
Closed -$33.5K – 427
2026
Q1 		$33.5K Hold
75
– – 0.02% 188
2025
Q4 		$34K Hold
75
– – 0.02% 178
2025
Q3 		$29.4K Hold
75
– – 0.02% 195
2025
Q2 		$33.4K Hold
75
– – 0.02% 176
2025
Q1 		$36.4K Hold
75
– – 0.02% 162
2024
Q4 		$30.2K Hold
75
– – 0.02% 178
2024
Q3 		$34.9K Hold
75
– – 0.02% 177
2024
Q2 		$35.2K Buy
75
+25
+50% +$10.9K 0.02% 171
2024
Q1 		$20.9K Buy
+50
New +$21.1K 0.01% 220

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Founders Capital Management (Texas)'s VRTX Position: Q2 2026 in Review

Founders Capital Management (Texas) sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 75 shares — an estimated $33.5K sold.

Founders Capital Management (Texas) first reported a position in VRTX in Q1 2024 and held it in 9 quarters. The position peaked at $36.4K in Q1 2025. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Founders Capital Management (Texas) reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Founders Capital Management (Texas) sold 75 Vertex Pharmaceuticals shares in Q2 2026, an estimated $33.5K.
  • Founders Capital Management (Texas) first reported a position in Vertex Pharmaceuticals in Q1 2024 and held it in 9 quarters.
  • Founders Capital Management (Texas)'s Vertex Pharmaceuticals position peaked at $36.4K in Q1 2025.
  • 334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Founders Capital Management (Texas)'s 13F filing for Q2 2026, filed 21 Jul 2026.